|
rs1057519864
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Using multiple prostate cancer cell lines, we showed that catalytic Topo II inhibitors, ICRF187 and ICRF193 inhibited transcription activities of the wild-type AR, mutant ARs (F876L and W741C) and the AR-V7 splice variant.
|
26009876 |
2015 |
|
rs6152
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To investigate the relationships between male androgenetic alopecia, androgen receptor (AR) gene polymorphism (SNP rs6152) and clinical characteristics of BPH and prostate cancer.
|
24665929 |
2015 |
|
rs137852593
|
|
|
0.740 |
GeneticVariation |
BEFREE |
To estimate the possible involvement of the prostate cancer predisposing AR Arg726Leu germ-line mutation in MBC, this mutation was tested in 117 MBC patients.
|
12602915 |
2003 |
|
rs137852578
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al.Nature Med.2000, 6, 703-6).
|
11906285 |
2002 |
|
rs864622007
|
|
|
0.830 |
GeneticVariation |
BEFREE |
This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al.Nature Med.2000, 6, 703-6).
|
11906285 |
2002 |
|
rs1034866440
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
|
rs137852569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
|
rs137852593
|
|
|
0.740 |
GeneticVariation |
BEFREE |
The present study indicates that the R726L substitution in the AR may confer an up to 6-fold increased risk of prostate cancer and may contribute to cancer development in up to 2% of Finnish prostate cancer patients.
|
11103816 |
2000 |
|
rs137852578
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The cortisol/cortisone-responsive AR (AR(ccr)) has two mutations (L701H and T877A) that were found in the MDA PCa human prostate cancer cell lines established from a castrated patient whose metastatic tumor exhibited androgen-independent growth.
|
11956172 |
2002 |
|
rs864622007
|
|
|
0.830 |
GeneticVariation |
BEFREE |
The cortisol/cortisone-responsive AR (AR(ccr)) has two mutations (L701H and T877A) that were found in the MDA PCa human prostate cancer cell lines established from a castrated patient whose metastatic tumor exhibited androgen-independent growth.
|
11956172 |
2002 |
|
rs137852578
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The androgen-mediated repression of hTERT is abrogated in a human prostate cancer cell line exhibiting hormone-dependent growth, which expresses a mutant AR (T877A) frequently occurring in prostate cancer.
|
17991730 |
2008 |
|
rs1034866440
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
|
rs137852569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
|
rs137852578
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The T877A mutant of the AR frequently found in advanced cases of prostate cancer displays an exaggerated stimulation of transcriptional activity by CDK6.
|
15790678 |
2005 |
|
rs137852578
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Taken together, these findings provide novel insights into the AR dysfunctions resulting from the T877A mutation and functionally similar AR alterations may provide selective cell growth/survival advantage for CaP progression.
|
16636679 |
2006 |
|
rs137852581
|
|
|
0.720 |
GeneticVariation |
BEFREE |
T can nevertheless acquire DHT-like activity through an AR helix-10 H874Y prostate cancer mutation.
|
17591767 |
2007 |
|
rs6624304
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Swedish men with the variant AR haplotype H2, tagged by rs6624304, have significantly lower risk of PCa compared to those with the more common variant.
|
28176139 |
2017 |
|
rs137852581
|
|
|
0.720 |
GeneticVariation |
BEFREE |
SfaNI digestion of AR exon H DNA from normal but not from prostate cancer tissue indicated H874Y is a somatic mutation that occurred before the initial tumor transplant.
|
9092797 |
1997 |
|
rs137852578
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groups.
|
25409505 |
2014 |
|
rs864622007
|
|
|
0.830 |
GeneticVariation |
BEFREE |
Our results indicate that the specific amino acid residue at position 701, its interaction with the backbone of Ser(778), and the steroidal 17alpha-hydroxyl group of the ligand are all important for the distinct transcriptional responses to progesterone and cortisol of AR mutants, including the prostate cancer mutant L701H.
|
20007693 |
2010 |
|
rs137852578
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Mutation (T877A) of the AR gene found in an androgen-sensitive prostate cancer cell line, LNCaP, has been postulated to be involved in hypersensitivity and loss of specificity for androgen.
|
17312014 |
2007 |
|
rs976306779
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Moreover, the results confirm the oncogenic nature of S100P in prostate cancer and suggest that the protein may directly confer resistance to chemotherapy.
|
18452169 |
2008 |
|
rs777787518
|
|
|
0.010 |
GeneticVariation |
BEFREE |
MDA prostate cancer 118a and MDA prostate cancer 118b cells carry a mutated β-catenin at codon 32 (D32G).
|
22298898 |
2012 |
|
rs137852578
|
|
|
0.800 |
GeneticVariation |
BEFREE |
It may be particularly effective against prostate cancer cells with the T878A AR mutation but may also enhance degradation of wild-type AR in vivo through a combination of direct and indirect mechanisms.
|
24874833 |
2014 |
|
rs137852578
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer.
|
19856921 |
2009 |